EVALUATING THE EFFICACY AND CEFETY OF INDUCTION CHEMOTHERAPY REGIMEN FOR PATIENTS WITH III-IV STAGE LARYNGEAL AND HYPOPHARYNGEAL CANCER
Main Article Content
Abstract
Objective: Evaluate the treatment effectiveness and describe side effects of pre-adjuvant chemotherapy regimens in stages III-IV laryngeal and hypopharyngeal squamous carcinoma. Methods: Including 30 patients diagnosed with stages III and IV laryngeal and hypopharyngeal squamous carcinoma. Self-controlled clinical intervention study. Results: All patients were men, average age 55.9±6 years old, mainly presented due to painful and difficult swallow. 24/30 patients (80%) had hypopharyngeal cancer. After 3 cycles of neoadjuvant chemotherapy, 2/30 patients (7%) had a complete response, 27/30 patients (90%) had a partial or stable response, and only 1/30 (3%) patient were badly progressed. The main side effects were nausea in 25/30 patients (83.3%), fatigue in 25/30 patients (83.3%), and hair loss in 30/30 patients (100%). There were 10/30 patients (33.3%) with grade III and IV neutropenia and 4/30 patients (13.3%) with renal dysfunction below 60ml/min/1.73m2 of skin. Conclusions: The research shows that after 3 cycles of neoadjuvant chemotherapy, the majority of patients responded partially or were stable, with less symptoms and improved quality of life. Side effects of chemical drugs are safe and acceptable during treatment.
Article Details
References
2. Haddad, R., A. O'Neill, G. Rabinowits, et al. 2013. "Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial." Lancet Oncol 14(3):257-264.
3. Cohen, E. E., T. G. Karrison, M. Kocherginsky, et al. 2014. "Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer." J Clin Oncol 32(25):2735-2743.
4. Vermorken, J. B., E. Remenar, C. van Herpen, et al. 2007. "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer." N Engl J Med 357(17):1695-1704.
5. Posner, M. R., D. M. Hershock, C. R. Blajman, et al. 2007. "Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer." N Engl J Med 357(17):1705-1715.